Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36).
Yokoyama H, Araki S, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H, Maegawa H, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group. Yokoyama H, et al. Among authors: sugimoto k. Diabetes Res Clin Pract. 2015 Sep;109(3):485-92. doi: 10.1016/j.diabres.2015.06.005. Epub 2015 Jul 16. Diabetes Res Clin Pract. 2015. PMID: 26261056
Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25).
Yokoyama H, Araki S, Haneda M, Matsushima M, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H, Maegawa H, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group. Yokoyama H, et al. Among authors: sugimoto k. Diabetologia. 2012 Jul;55(7):1911-8. doi: 10.1007/s00125-012-2536-y. Epub 2012 Apr 4. Diabetologia. 2012. PMID: 22476921
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K; PROCEED trial investigators. Tanaka A, et al. Among authors: sugimoto k. Cardiovasc Diabetol. 2020 Jun 13;19(1):85. doi: 10.1186/s12933-020-01065-w. Cardiovasc Diabetol. 2020. PMID: 32534578 Free PMC article.
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Tanaka A, Okada Y, Torimoto K, Kamei N, Hirai H, Kono T, Sugimoto K, Teragawa H, Taguchi I, Maruhashi T, Sonoda S, Kurozumi A, Inagaki S, Oshita C, Hisauchi I, Takahashi K, Higashi Y, Shimabukuro M, Node K; PROCEED Trial Investigators. Tanaka A, et al. Among authors: sugimoto k. Diabetes Metab. 2023 Jul;49(4):101447. doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26. Diabetes Metab. 2023. PMID: 37116858 Clinical Trial. No abstract available.
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, Ishizu T, Ueda S, Kitakaze M, Murohara T, Node K; PROTECT study investigators. Tanaka A, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):165-172. doi: 10.1093/ehjcvp/pvac059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36308299 Free PMC article. Clinical Trial.
Comparison of T1 Mapping on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging With Conventional Functional Liver Reserve Indices and Technetium-99m Galactosyl Serum Albumin Scintigraphy.
Takase K, Saito K, Tajima Y, Araki Y, Uchida K, Hakamata D, Sugimoto K, Yuunaiyama D, Takara Y. Takase K, et al. Among authors: sugimoto k. Cureus. 2024 Oct 6;16(10):e70952. doi: 10.7759/cureus.70952. eCollection 2024 Oct. Cureus. 2024. PMID: 39502988 Free PMC article.
3,454 results